๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE

โœ Scribed by Birkmayer, W; Riederer, P; Ambrozi, L; Youdim, M.B.H

Book ID
122871587
Publisher
The Lancet
Year
1977
Tongue
English
Weight
655 KB
Volume
309
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Levodopa alone and in combination with a
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madoparยฎ) in the treatment of Parkinson's disease
โœ U. K. Rinne; E. Birket-Smith; E. Dupont; E. Hansen; M. Hyyppรค; R. Marttila; B. M ๐Ÿ“‚ Article ๐Ÿ“… 1975 ๐Ÿ› Springer ๐ŸŒ English โš– 528 KB

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide prov

Dementia and treatment with L-dopa in Pa
Dementia and treatment with L-dopa in Parkinson's disease
โœ M. Hietanen; Dr. H. Terรคvรคinen ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 536 KB

We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L-dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who w